An alternative multidrug regimen for multibacillary Hansen's disease: a case report

Area of Science:

• Infectious Diseases
• Dermatology
• Microbiology

Background:

• Leprosy (Hansen's disease) is a significant global health challenge, particularly in resource-limited settings.
• Caused by Mycobacterium leprae and Mycobacterium lepromatosis, it affects skin and nerves, leading to severe sequelae if untreated.
• Current multidrug therapy for multibacillary leprosy has limitations including high pill burden and side effects, impacting patient adherence.

Observation:

• A case of multibacillary leprosy is presented in a 30-year-old Hispanic male immigrant to the USA.
• The patient presented with progressive nodular skin lesions on the face and extremities.
• He received a monthly regimen of rifampin, moxifloxacin, and minocycline.

Findings:

• The patient exhibited significant improvement in cutaneous lesions following treatment.
• No signs of reversal reaction or erythema nodosum leprosum were observed during follow-up.
• This indicates a positive initial response to the novel therapeutic regimen.

Implications:

• This case supports the use of rifampin, moxifloxacin, and minocycline as an alternative leprosy treatment.
• Further research is essential to establish the long-term efficacy and safety of this regimen.
• Monitoring for delayed immunologic reactions post-treatment is crucial for comprehensive patient care.